Oncology
Refine Search
Pharmaceutical
British pharma major GSK has surpassed market expectations, announcing a 10% increase in total sales, and a 16% rise when excluding COVID-19 impacts. 1 November 2023
Biotechnology
US biotech Seagen today reported financial results for the third quarter ended September 30, 2023. 1 November 2023
Biotechnology
French biotech Cellectis saw its shares rocket 149% to 2.24 euros by mid-afternoon trading today, on news of a collaboration an investment deal with UK pharm major AstraZeneca. 1 November 2023
Biotechnology
US biotech giant Amgen saw its shares fall by 4.4% to $251.44 on Tuesday, after it announced financial results for the third quarter of 2023. 1 November 2023
Biotechnology
UK clinical-stage biotech STORM Therapeutics, which is targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has appointed Marguerite Hutchinson as its chief business officer. 1 November 2023
Biotechnology
Danish biotech company Evaxion has announced initial results from a Phase II trial of the first five metastatic melanoma patients treated with EVX-01, a peptide-based personalized cancer vaccine. 31 October 2023
Pharmaceutical
US pharma giant Pfizer was trading more than 1% lower during Tuesday morning’s trading in New York, following the release of financial results. 31 October 2023
Biotechnology
UK drugmaker GSK has announced positive headline results from a planned analysis of part one of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial. 31 October 2023
Biotechnology
Belgian biotech Galapagos has agreed to sell its Jyseleca (filgotinib) business to Italian drugmaker Alfasigma. 31 October 2023
Biotechnology
Gilead Sciences Kite unit has agreed a collaboration and research deal with Epicrispr Biotechnologies (Epic Bio), using the latter’s proprietary gene regulation platform to develop next-generation cancer cell therapies. 31 October 2023
Biosimilars
Indian pharmaceutical companies are demonstrating a growing commitment to advancing cancer treatment through substantial investments in biologics. 31 October 2023
Biotechnology
Indian drugmaker Intas Pharmaceuticals has inked an exclusive deal with Shanghai Henlius Biotech for the development and commercialization of serplulimab in Europe and India. 30 October 2023
Biotechnology
German life sciences and pharma firm Merck KGaA today announced a strategic collaboration with China’s Jiangsu Hengrui Pharmaceuticals. 30 October 2023
Pharmaceutical
French drugmaker Ipsen has presented its sales performance for the year-to-date 2023. 30 October 2023
Biotechnology
M&A news last week saw Swiss pharma giant Roche announce last Monday it had agreed to acquire Roivant company Telavant and its TL1A-directed antibody RVT-3101 for $7.1 billion. Among research news, Johnson & Johnson presented much awaited new data at the European Society of Medical Oncology (ESMO) on its lung cancer drug Rybrevant. And Japan’s Eisai and US Biotech Biogen released new data for a subcutaneous formulation of their Alzheimer’s disease drug Leqembi at an AD clinical trials conference. Also of note, US pharma major Eli Lilly gained approval from the US Food and Drug Administration (FDA) for its ulcerative colitis drug Omvoh. 29 October 2023
Pharmaceutical
In a third-quarter financial results season when most pharma companies have pleased shareholders with better-than-expected figures, the reaction to Sanofi’s presentation on Friday has provided a stark contrast. 27 October 2023
Pharmaceutical
US pharma major AbbVie’s shares were down 3.3% at $140.24 early today, after it released financial results for the third quarter of 2023. 27 October 2023
Pharmaceutical
Pharma giant Merck & Co was trading more than 2% higher Thursday lunchtime, as the firm released financial results. 26 October 2023
Pharmaceutical
US Pharma major Bristol Myers Squibb today reported results for the third quarter of 2023, which the company says reflect significant pipeline progress and advances in the portfolio renewal strategy. 26 October 2023
Biotechnology
Independent data monitors have recommended that French microbiome specialist MaaT Pharma continues its Phase III ARES study without modification. 26 October 2023
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze